Empagliflozin for heart failure with preserved left ventricular ejection fraction with and without diabetes

HIGHLIGHTS

• who: Circulation and collaborators from the National and Kapodistrian University of Athens School of Medicine, Athens University Hospital Attikon, Greece (GF.). Baylor Scott and White Research Institute, Dallas, TX (J.B.). Department of Medicine, University of Mississippi School of Medicine, Jackson (J.B.). University of Cyprus Medical School, Nicosia (D.F.). Centre d'Investigations Cliniques Plurithématique, Inserm, CHRU, CRIN INI-CRCT (Cardiovascular and Renal Clinical Trialists), Université de Lorraine, Nancy, France (F.Z., J.P.F.). Medical Department, Boehringer Ingelheim Norway KS, Asker (A.P.O.). Oslo Diabetes Research Center, Norway (A.P.O.). Cardiovascular Research . . .
  

   

  

  If you want to have access to all the content you need to log in!

  Thanks :)

  Username or Email

  Password

  Remember me

  Lost your password?

  If you don't have an account, you can create one here.